Alpenglow Biosciences, a Seattle biotech startup that develops 3D spatial biology imaging technology, announced Thursday that it secured a $2 million research grant from the National Institute of Health, along with a $1 million investment to further develop its platform.
- The company’s co-founder, Jonathan Liu, also received a contract for up to $21 million to develop technology for precision tumor removal. This is part of the Biden Administration’s Cancer Moonshot initiative.
- Founded in 2018 and originally known as Lightspeed Microscopy, the 20-person company spun out of the University of Washington and is currently led by CEO Nicholas Reder. The company was co-founded by Liu, who is a professor at UW, along with Adam Glaser and Lawrence True.
- Alpenglow has a workforce of 20 employees. The company’s investors include Alexandria, Dynamk Capital, First In Ventures, Hamamatsu, Mayo Clinic, and WRF Capital.
